Canaccord Genuity Maintains Their Buy Rating on Kaleido Biosciences (KLDO)

By Jason Carr

Canaccord Genuity analyst John Newman maintained a Buy rating on Kaleido Biosciences (KLDOResearch Report) yesterday and set a price target of $19.00. The company’s shares closed last Wednesday at $9.82.

According to, Newman is a 5-star analyst with an average return of 22.9% and a 47.4% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Allogene Therapeutics, and Atara Biotherapeutics.

Currently, the analyst consensus on Kaleido Biosciences is a Strong Buy with an average price target of $18.10.

See today’s analyst top recommended stocks >>

Kaleido Biosciences’ market cap is currently $410.8M and has a P/E ratio of -4.00. The company has a Price to Book ratio of 11.43.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kaleido Biosciences, Inc. is a healthcare company, which focuses on leveraging the potential of the microbiome organ to treat disease and improve human health. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan in 2015 and is headquartered in Lexington, MA.